The third phase of trials of the Pfizer and BioNTech vaccine began in July.
The Pharmaceutical Company Pfizer said on Tuesday that it is not yet ready to publish the results of a late-stage trial of a potential COVID-19 vaccine that it is developing together with the German company BioNTech.
Pfizer CEO Albert Burla said the company could release the data as soon as this month. Still, the company’s presentation said the independent data monitoring committee, which is supposed to determine whether the trial was successful, has not yet conducted interim effectiveness analyses.
Before the opening of the trading session, the shares were trading unchanged at $ 37.93.
Earlier, US President Donald Trump said that the vaccine could be available before the November 3 election. Still, in recent weeks, his administration has said that the vaccine will be ready before the end of the year.
Pfizer hopes to become the first pharmaceutical company in the United States to present successful data on the results of late-stage trials of the COVID-19 vaccine, ahead of competitor Moderna. Pfizer and BioNTech began phase three trials involving 44,000 volunteers in late July.
The data monitoring Commission is expected to give the first assessment of the vaccine’s effectiveness after 32 trial participants become infected with the new coronavirus.
While the pandemic has reduced demand for several Pfizer drugs, investors keep a close eye on progress in vaccine development.